The Norwegian Antirheumatic Drug Register

NOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs (DMARDs) in clinical practice, by measuring disease activity, health related quality of life, function and joint damage, and to study the long-term safety of such treatment. Other objectives include the assessment of cost-effectiveness of treatment, to identify and and validate clinical, genetic and immunological predictors of efficacy and adverse events, to assess the impact of treatment with biological DMARDs on work participation and work productivity, to investigate different strategies for use of biological DMARDs, to assess the performance of different outcome measures, and to ensure a systematic and timely follow-up of patients treated with biological DMARDs.

NCT Number	NCT01581294
Lead Sponsor	Diakonhjemmet Hospital Collaborators: University Hospital of North Norway, St. Olavs Hospital, Lillehammer Hospital for Rheumatic Diseases, Vestre Viken Hospital Trust, Helse Forde
Conditions	Inflammatory Joint Diseases
Enrollment	15,000 participants
Start Date	2012-04
Primary Completion	2050-12 (estimated)
Study Completion	2050-12 (estimated)
Updated on ClinicalTrials.gov	2022-08-23